Omega-3 Fatty Acid Supplementation and Vascular Health Biomarkers - A Systematic Review and Meta-Analysis.
Cardiovascular diseases (CVDs) remain the leading global cause of death, partly due to vascular dysfunction. Dietary supplements, including omega-3 fatty acids, are suggested to support vascular health, but their therapeutic effectiveness and optimal dosing are still uncertain.
This systematic review and meta-analysis study assessed the efficacy and dose-response effects of omega-3 fatty acids on vascular health biomarkers in individuals with CVDs.
A comprehensive search of PubMed, Scopus, Web of Science, and the Cochrane Library was conducted through May 2025.
Eligible randomized controlled trials (RCTs) with a minimum intervention duration of four weeks.
Two reviewers independently extracted data and assessed study quality. Data were synthesized as weighted mean differences (WMDs) with 95% confidence intervals (CIs). Risk of bias was assessed using the Cochrane tool, and the certainty of the evidence (CoE) was appraised using the GRADE framework.
The pulse wave velocity (PWV), augmentation index (AIx), and flow-mediated dilation (FMD).
Twenty RCTs involving 1,208 participants were included, with 80% judged at low risk of bias. Omega-3 supplementation (0.3-4.7 g/day) showed no significant effect on PWV, including in subgroups with hypertension or established CVDs. In contrast, omega-3s improved AIx. FMD elevations were greater for eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA) than for alpha-linolenic acid. These findings were consistent across sensitivity analyses and supported by dose-response relationships, indicating that achieving approximately 1,650 mg EPA and 750 mg DHA may be important for optimizing vascular outcomes. The CoE ranged from moderate to low.
Omega-3 fatty acids may enhance endothelial function and reduce arterial wave reflection. Future trials with refined methods are needed to maximize clinical benefit.
Systematic review registered with PROSPERO, registration number CRD420251065121.
This systematic review and meta-analysis study assessed the efficacy and dose-response effects of omega-3 fatty acids on vascular health biomarkers in individuals with CVDs.
A comprehensive search of PubMed, Scopus, Web of Science, and the Cochrane Library was conducted through May 2025.
Eligible randomized controlled trials (RCTs) with a minimum intervention duration of four weeks.
Two reviewers independently extracted data and assessed study quality. Data were synthesized as weighted mean differences (WMDs) with 95% confidence intervals (CIs). Risk of bias was assessed using the Cochrane tool, and the certainty of the evidence (CoE) was appraised using the GRADE framework.
The pulse wave velocity (PWV), augmentation index (AIx), and flow-mediated dilation (FMD).
Twenty RCTs involving 1,208 participants were included, with 80% judged at low risk of bias. Omega-3 supplementation (0.3-4.7 g/day) showed no significant effect on PWV, including in subgroups with hypertension or established CVDs. In contrast, omega-3s improved AIx. FMD elevations were greater for eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA) than for alpha-linolenic acid. These findings were consistent across sensitivity analyses and supported by dose-response relationships, indicating that achieving approximately 1,650 mg EPA and 750 mg DHA may be important for optimizing vascular outcomes. The CoE ranged from moderate to low.
Omega-3 fatty acids may enhance endothelial function and reduce arterial wave reflection. Future trials with refined methods are needed to maximize clinical benefit.
Systematic review registered with PROSPERO, registration number CRD420251065121.
Authors
Norouzzadeh Norouzzadeh, Hasan Rashedi Hasan Rashedi, Hamidi Hamidi, Karimi-Javan Karimi-Javan, Nourian Nourian, Hasanpour Hasanpour, Anoushirvani Anoushirvani, Teymoori Teymoori
View on Pubmed